ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0508 • ACR Convergence 2021

    The Impact of Macrophages Stimulated with Malondialdehyde-Acetaldehyde And/or Citrulline Modified Proteins on Fibroblasts Activation

    Nozima Aripova, Michael Duryee, Evan Ryan, Peter Maloley, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: In rheumatoid arthritis (RA), chronic synovial inflammation is accompanied by fibrotic responses that together lead to pannus formation and progressive joint damage. Exposure to…
  • Abstract Number: 0507 • ACR Convergence 2021

    Tocilizumab in Patients with New Onset Polymyalgia Rheumatica (PMR-SPARE) – a Phase 2/3 Randomized Controlled Trial

    Michael Bonelli1, Helga Radner1, Josef Smolen1, Martina Durechova1, Jutta Stieger2, Rusmir Husic3, Andreas Kerschbaumer1, Christian Dejaco4 and Daniel Aletaha5, 1Medical University of Vienna, Vienna, Austria, 22nd Department of Medicine, Hietzing Hospital, Vienna, Austria, 3Medical University of Graz, Graz, Austria, 4Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, Brunico, Italy, 5Medical University Vienna, Vienna, Austria

    Background/Purpose: PMR is the second most common inflammatory rheumatic disease of people aged 50 years or older. Glucocorticoid therapy is highly effective, but many patients…
  • Abstract Number: 0502 • ACR Convergence 2021

    Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms

    Benjamin Hur1, Matthew Koster1, Jin Sung Jang1, Kenneth Warrington2 and Jaeyun Sung1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota

    Background/Purpose: Non-infectious aortitis may be a manifestation of systemic large vessel vasculitis such as giant cell arteritis (GCA) or may be a form of single…
  • Abstract Number: 0513 • ACR Convergence 2021

    Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood

    DeAnna Diaz1, Thomas Vazquez2, Christina Bax3, Jay Patel4, Madison Grinnell5, Emily Keyes6, Yubin Li5 and Victoria Werth7, 1Philadelphia College of Medicine, Philadelphia, PA, 2FIU Wertheim College of Medicine, Virginia Beach, VA, 3Corporal Michael J. Crescenz VAMC/ Department of Dermatology, U Penn, Philadelphia, PA, 4Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, 5Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, 6Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Our group has previously shown that Spirulina, a popular herbal supplement with purported immune boosting effects, is temporally associated with dermatomyositis (DM) onset and…
  • Abstract Number: 0512 • ACR Convergence 2021

    Peficitinib and Filgotinib Inhibit Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes

    Yuzo Ikari, Takeo Isozaki, Kuninobu Wakabayashi and Tsuyoshi Kasama, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

    Background/Purpose: Peficitinib and filgotinib are novel Janus kinase (JAK) inhibitors developed for the treatment of rheumatoid arthritis (RA). Peficitinib inhibits all JAKs, especially JAK3. Filgotinib,…
  • Abstract Number: 0510 • ACR Convergence 2021

    Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes

    Brittany Wordekemper, Nozima Aripova, Michael Duryee, Eric Daubach, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Malondialdehyde (MDA) is produced in response to oxidative stress and is associated with inflammation and disease pathogenesis. MDA can break down and form acetaldehyde…
  • Abstract Number: 0514 • ACR Convergence 2021

    Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts

    Ruby Siegel1, Anil singh1, Judy Vinh1, H. Mark Kenney2, Edward Schwarz3, David Fox4, Sadik Khuder5 and Salah-uddin Ahmed1, 1Washington State University, Spokane, WA, 2University of Rochester Medical Center, Rochester, NY, 3University of Rochester, Rochester, NY, 4Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 5Department of Medicine and Public Health, University of Toledo,, Toledo, OH

    Background/Purpose: TNF-α drives RA synovial fibroblast (RASF)-mediated hyperplasia and joint tissue destruction. Extracellular sulfatase-2 (Sulf-2) influences receptor/ligand binding and subsequent signaling of chemokines, cytokines, and…
  • Abstract Number: 0516 • ACR Convergence 2021

    Dual Fibroblast Transdifferentiation Mediated by Type I Interferon: Application to Anti-Ro Mediated Congenital Heart Block

    Christina Firl1, Miao Chang2, Jill Buyon3 and Robert Clancy1, 1NYU Grossman School of Medicine, New York, NY, 2NYU Langone Health, New York, NY, 3NYU School of Medicine, New York, NY

    Background/Purpose: Linking inflammation to fibrosis, a common end stage feature of many autoantibody mediated rheumatic diseases, remains a challenge. Indeed the signature hallmark of anti-Ro…
  • Abstract Number: 0515 • ACR Convergence 2021

    The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts

    Ruby Siegel, Sang Han and Salah-uddin Ahmed, Washington State University, Spokane, WA

    Background/Purpose: Recent unpublished findings from our lab show that the extracellular enzyme sulfatase-2 (Sulf-2) facilitates pro-inflammatory TNF-α signaling which activates rheumatoid arthritis synovial fibroblasts (RASFs).…
  • Abstract Number: 0511 • ACR Convergence 2021

    Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B

    Jorge Romo-Tena1, Jose Esparza-Lopez2, Carmelo Carmona-Rivera3, Luz P blanco3, Mariana Kaplan4 and María de Jesús Ibarra-Sánchez2, 1INNSZ / NIAMS, Mexico City, Mexico, 2INNSZ, Mexico City, Mexico, 3NIAMS, Bethesda, MD, 4National Institutes of Health, Bethesda, MD

    Background/Purpose: Endothelial dysfunction is a hallmark in the pathogenesis of many inflammatory diseases. The endothelial-to-mesenchymal transition (EndoMT) is a process where endothelial cells lose their…
  • Abstract Number: 0505 • ACR Convergence 2021

    Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States

    Despina Michailidou1, Tianyu Zhang2, Pavlos Stamatis3 and Bernard Ng4, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Department of Biostatistics, University of Washington, Seattle, WA, 3Lund University, Lund, Sweden, 4Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA

    Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated…
  • Abstract Number: 0486 • ACR Convergence 2021

    A Practical Approach to Competency-based Evaluations and Milestone Mapping for Adult Rheumatology Fellowship Programs

    Grant hughes1, Sarah Chung1, Elizabeth Wahl2, Jenna Thomason1, Bernard Ng3, Ingeborg Sacksen4 and Alison Bays1, 1University of Washington, Seattle, WA, 2VA Puget Sound Healthcare System, Seattle, WA, 3Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA, 4University of Washington, Bellingham, WA

    Background/Purpose: The American College of Rheumatology has developed 14 Entrustable Professional Activities (EPAs) for Adult Rheumatology that define broad clinical competency goals for fellowship. At…
  • Abstract Number: 0457 • ACR Convergence 2021

    Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination

    Michael Paley1, Parakkal Deepak2, Wooseob Kim2, Monica Yang3, Alex Carividi3, Emanuel Demissie3, Alia A. El-Qunni,2, Alem Haile2, Katherine Huang2, Baylee Kinnett2, Mariel Liebeskind2, Zhouming Liu2, Lily E. McMorrow2, Diana Paez3, Niti Pawar3, Dana Perantie2, Rebecca E. Schriefer2, Shannon Sides2, Mahima Thapa2, Sewuese Akuse4, Samantha Burdess2, Abbey Rose2, Lynne Mitchell2, Salim Chahin2, Matthew Ciorba2, Jonathan Graf5, Patricia Katz3, Mehrdad Matloubian3, Jane O'Halloran2, Rachel Presti2, Gregory Wu2, Sean Whelan2, William Buchser2, Lianne Gensler6, Mary Nakamura7, Ali H Ellebedy2 and Alfred Kim2, 1Washington University in St. Louis, Olivette, MO, 2Washington University School of Medicine, St. Louis, MO, 3University of California San Francisco, San Francisco, CA, 4Washington University School of Medicine, St Louis, MO, 5Ucsf, San Francisco, CA, 6Department of Rheumatology, University of California San Francisco, San Francisco, CA, 7UCSF/SFVAHCS, San Francisco, CA

    Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
  • Abstract Number: 0394 • ACR Convergence 2021

    Hyperspectral Imaging in Systemic Sclerosis-Raynaud Phenomenon

    Akash Gupta1, Shannon Teaw2, Alyssa Williams2, F. Perry Wilson3, Brandon Sumpio4, Bauer Sumpio4 and Monique Hinchcliff5, 1Department of Medicine, Yale University School of Medicine, New Haven, CT, 2Section of Rheumatology, Allergy & Immunology, Department of Medicine, Yale School of Medicine, New Haven, CT, 3Section of Nephrology, Department of Medicine, Yale School of Medicine, New Haven, CT; Department of Medicine Clinical and Translational Research Accelerator Yale School of Medicine, New Haven, CT, 4Division of Vascular Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT, 5Yale School of Medicine, Westport, CT

    Background/Purpose: Raynaud phenomenon (RP), a microcirculatory, vasospastic disorder, may be primary or secondary to an autoimmune disease [e.g., an early indicator of systemic sclerosis (SSc)].…
  • Abstract Number: 0269 • ACR Convergence 2021

    Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis

    Tate Johnson1, Michael Duryee2, Carlos Hunter2, Punyasha Roul2, Yangyuna Yang2, Jeremy Sokolove3, William Robinson4, Joshua Baker5, Geoffrey Thiele2, Ted Mikuls2 and Bryant England2, 1University of Nebraska Medical Center, Elkhorn, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Stanford University School of Medicine, Berwyn, PA, 4Stanford University, Stanford, CA, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
  • « Previous Page
  • 1
  • …
  • 584
  • 585
  • 586
  • 587
  • 588
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology